NexImmune researches, develops and commercializes T cell-based immunotherapies for the treatment of cancer. Read more
NexImmune's Competitors, Revenue, Number of Employees, Funding and Acquisitions
574 Followers on Owler
CEO
Scott P. Carmer
Est. Annual Revenue
Est. Employees
Sector
Headquarters
TOP COMPETITORS OR ALTERNATIVES
Missing a competitor? Contribute!
Aura Biosciences is NexImmune's #1 competitor. Aura Biosciences's headquarters is in Cambridge, Massachusetts, and was founded in 2009. Like NexImmune, Aura Biosciences also works within the Biotechnology sector. Aura Biosciences generates 168% of NexImmune's revenue.
Weigh-in!
Help the Owler community know moreExplore companies in similar locations and sectors
Trending News for NexImmune and NexImmune's Competitors
Today 2:02 AM
FinanzNachrichten
Novartis: Phase III Trials Shows Superior Efficacy Of Ofatumumab In Relapsing Multiple Sclerosis
BASEL (dpa-AFX) - Novartis said that Phase III ASCLEPIOS trials demonstrated superior efficacy of ofa... See more »
August 5, 2020
Business Wire
bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results... See more »
August 4, 2020
centralcharts
Jounce Therapeutics to Participate in a Fireside Chat at BTIG Virtual Biotechnology Conference 2020
CAMBRIDGE, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clini... See more »
Acquisitions
No recent acquisitions found related to NexImmune
NexImmune Funding History
Since NexImmune was founded in 2011, it has participated in 7 rounds of funding. In total NexImmune has raised $35.0M. NexImmune's last funding round was on Jan 2019 for a total of $7.8M
ROUND
FUNDING DATE
AMOUNT
INVESTORS
Equity
Jan 2019
$7.8M
ArrowMark Partners
Debt
Feb 2015
$2M
Debt
Jul 2014
$3M
Debt
Dec 2013
$250K
-
Total Funding: $35M
Since NexImmune was founded in 2011, it has participated in 7 rounds of funding. In total NexImmune has raised $35.0M. NexImmune's last funding round was on Jan 2019 for a total of $7.8M
Investments
No recent investments found related to NexImmune
NexImmune News
December 16, 2019Benzinga
NexImmune Appoints Sol Barer as Chairman of the Board of Directors
GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical co... See more »
December 2, 2019MarketScreener
NexImmune Management to Present at Upcoming Conferences
(marketscreener.com) GAITHERSBURG, Md., Dec. 02, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical stage... See more »
April 29, 20194-traders
Multiple Myeloma Research Foundation (MMRF) Venture Philanthropy Fund Invests in NexImmune to Advance Novel Immunotherapy Candidate Into Clinical Trials
(marketscreener.com) GAITHERSBURG, Md. and NORWALK, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- NexImmu... See more »
April 5, 20194-traders
NexImmune Management to Present at Upcoming Conferences
(marketscreener.com) GAITHERSBURG, Md., April 05, 2019 (GLOBE NEWSWIRE) -- NexImmune, an emerging lea... See more »
February 27, 2019The Business Journals: Baltimore
Gaithersburg biotech raising more funding after $25M round
The company has already raised about $40 million to date.... See more »
December 11, 2018Benzinga
NexImmune Granted Key US Patent for Core E+E Technology
GAITHERSBURG, Md., Dec. 11, 2018 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of an... See more »
December 5, 2018FIRSTWORD PHARMA
NexImmune Completes Sr. Leadership Team with New VP Hires
NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced the hir... See more »
NexImmune Press Releases
April 5, 2019centralcharts
NexImmune Management to Present at Upcoming Conferences
NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that Sc... See more »
April 5, 2019streetinsider
NexImmune Management to Present at Upcoming Conferences
NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that Sc... See more »
December 11, 2018centralcharts
NexImmune Granted Key US Patent for Core E+E Technology
“Using our proprietary E+E technology to generate antigen-specific T cells represents a uniquely diff... See more »
April 24, 2018PRWeb
Dr. Daniel Bednárik Heads NexImmune's Molecular Engineering & Protein Design effort.
Dr. Daniel Bednárik heads NexImmune's Molecular Engineering & Protein Design programs for AIM-ACT and... See more »
October 17, 2017GlobeNewswire
NexImmune and The Leukemia & Lymphoma Society enter partnership for the development of AIM ACT in AML patients
GAITHERSBURG, Md., Oct. 17, 2017 (GLOBE NEWSWIRE) -- NexImmune and The Leukemia & Lymphoma Society (L... See more »
October 17, 2017econotimes
NexImmune and The Leukemia & Lymphoma Society enter partnership for the development of AIM ACT in AML patients
NexImmune and The Leukemia & Lymphoma Society (LLS) have entered a partnership to advance the Company... See more »
Headquarters
Trending Companies
IN THE NEWS
LightInTheBox.com | OptionSoft | Ayoconnect | TerrAscend | Eli Lilly | Drayton Manor Park | DyeMansion | Exxon Mobil | NCBA CLUSA | Android | Coca-Cola | Huawei | TEVA Pharmaceuticals | Tencent | Sinclair Broadcast Group | FanDuel | Sanofi | Electronic Arts | Manitowoc | Real Madrid | WhiteHat Jr | Jam Face | Samsung | Micron | Xiaomi | Telstra Ventures | Obiectivo Technology S.r.l | Phinma | UniCredit | Revionics | Krisp | Nexa3D | American Water | Amdocs | Coda | BYJU'S | eBay | Hatchdetroit | Envair | Bristol Myers Squibb | YouTube | Livongo Health | OneGlobal Broking | Peabody | NY&C Closet | CardioMech | TravelCenters of America | Rollic | Cummins | Facebook
PEOPLE ALSO VIEWED
Allied Integrated Marketing | AmSan | Intersys | SREI | Texas Electronics | Vanuston Intelligence | Axicom | Proventeq | Responsible Works | Explorys | HardTech Labs | Air 21 | Placelocal | Ampli5 Scopes Optics Lasers | eOne | Avteg | Datical | The Wp Guy | Vogue Institute of Fashion Technology | Sledge | Snider-Blake | GR8 | Yhasi Luxury Hair Company | Delcrest | Clean Freaks Cleaning Services | Slaylebrity | Amino Tech Labs | Shabby Fabrics | Rollinsons Home Center | Impel Airport Services Sp. Z O.o
Summary
ABOUT
Overview
NexImmune researches, develops and commercializes T cell-based immunotherapies for the treatment of cancer. NexImmune was founded in 2011. NexImmune's headquarters is located in Gaithersburg, Maryland, USA 20877. It has raised 35.0M in 7 rounds. The l...
CEO
NexImmune's CEO, Scott P. Carmer, currently has an approval rating of 91%. NexImmune's primary competitors are Aura Biosciences, Juno & Perthera.Website
neximmune.comFrequently Asked Questions about NexImmune
When was NexImmune founded?
NexImmune was founded in 2011Who is NexImmune's CEO?
NexImmune's CEO is Scott P. CarmerHow much revenue does NexImmune generate?
NexImmune generates $22M in revenueHow much funding does NexImmune have?
NexImmune has historically raised $35M in funding
Where is NexImmune's headquarters?
NexImmune's headquarters is in Gaithersburg Maryland, USAHow many employees does NexImmune have?
NexImmune has 150 employeesWhat sector does NexImmune operate in?
NexImmune is in BiotechnologyWho are NexImmune's competitors?
NexImmune's top competitors are Aura Biosciences, Juno, Perthera
